| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8562979 | APTALIS PHARMA US | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8246950 | APTALIS PHARMA US | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8221747 | APTALIS PHARMA US | Stable pancreatic enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562978 | APTALIS PHARMA US | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US7658918 | APTALIS PHARMA US | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562980 | APTALIS PHARMA US | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562981 | APTALIS PHARMA US | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
Zenpep is owned by Aptalis Pharma Us.
Zenpep contains Pancrelipase (Amylase;Lipase;Protease).
Zenpep has a total of 7 drug patents out of which 0 drug patents have expired.
Zenpep was authorised for market use on 25 March, 2014.
Zenpep is available in capsule, delayed release;oral dosage forms.
Zenpep can be used as treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.
Drug patent challenges can be filed against Zenpep from 27 August, 2013.
The generics of Zenpep are possible to be released after 20 February, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2014 |
Drugs and Companies using PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) ingredient
NCE-1 date: 27 August, 2013
Market Authorisation Date: 25 March, 2014
Treatment: Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions
Dosage: CAPSULE, DELAYED RELEASE;ORAL
ZENPEP family patents
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8562978 | ZENPEP | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562980 | ZENPEP | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562981 | ZENPEP | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8221747 | ZENPEP | Stable pancreatic enzyme compositions |
Feb, 2028
(3 years from now) | |
| US8562979 | ZENPEP | Stable digestive enzyme compositions |
Feb, 2028
(3 years from now) | |
Zenpep is owned by Zenpep.
Zenpep contains Pancrelipase (Amylase;Lipase;Protease).
Zenpep has a total of 5 drug patents out of which 0 drug patents have expired.
Zenpep was authorised for market use on 25 March, 2014.
Zenpep is available in capsule, delayed release;oral dosage forms.
Zenpep can be used as treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions.
Drug patent challenges can be filed against Zenpep from 27 August, 2013.
The generics of Zenpep are possible to be released after 20 February, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2014 |
Drugs and Companies using PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) ingredient
NCE-1 date: 27 August, 2013
Market Authorisation Date: 25 March, 2014
Treatment: Treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions
Dosage: CAPSULE, DELAYED RELEASE;ORAL
ZENPEP family patents